Groww Logo
Home>US Stocks>BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Healthcare
$78.93
+ $0.15 (0.19%) 1D
1D
1W
1M
1Y
3Y
5Y

Performance

Today’s Low
$
    Today’s High
    $
    52W Low
    $
      52W High
      $
      Open PricePrev. CloseVolumeAvg. Volume
      $78.57$78.9328,5331,143,052

      Fundamentals

      Market Cap$14.60B
      P/B Ratio3.3
      P/E Ratio371.1
      Enterprise Value$15.07B
      Div. Yield0.00%
      Book Value23.87
      EPS(TTM)0.21
      ROE0.90%
      Understand Fundamentals

      About the Company

      BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis
      BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.
      ...Read more
      OrganisationBioMarin Pharmaceutical Inc
      IndustryBiotechnology
      HeadQuartersSan Rafael, CA

      Company Financials

      *All values are in Million $
      No Graph Data To Display
      Quarterly
      Yearly
      See Details

      FAQs on BioMarin Pharmaceutical Inc

      Can I Buy BioMarin Pharmaceutical Inc Shares in India?

      Yes, BioMarin Pharmaceutical Inc shares can be bought in India by opening an international trading account with Groww.

      How to Buy BioMarin Pharmaceutical Inc Shares in India?

      One can easily invest in BioMarin Pharmaceutical Inc shares from India by: Direct Investment - Opening an international trading account with Groww which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy BioMarin Pharmaceutical Inc shares. Indirect Investment - Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of BioMarin Pharmaceutical Inc.

      What is the Share Price of BioMarin Pharmaceutical Inc?

      The share price of BioMarin Pharmaceutical Inc is in Dollars and if you are investing from India, you can always check the INR valuation before investing. The current BioMarin Pharmaceutical Inc share price is $78.93 as of 26 May ‘22

      What is the Market Cap of BioMarin Pharmaceutical Inc?

      The BioMarin Pharmaceutical Inc market cap is $14.60B as of 26 May ‘22

      What is the PE and PB ratio of BioMarin Pharmaceutical Inc?

      The PE and PB ratio of BioMarin Pharmaceutical Inc is 371.1 and 3.3 as of 26 May ‘22
      ⓒ 2016-2022 Groww. All rights reserved, Built with in India
      MOST POPULAR ON GROWWVERSION - 2.4.0
      STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
      MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI

      ABOUT GROWW